November 20, 2019 / 12:37 PM / a month ago

UPDATE 1-Bristol-Myers misses main goal of late-stage skin cancer trial

(Adds share price, trial details)

Nov 20 (Reuters) - Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.

The company said the trial will continue unchanged as per the recommendation of a data monitoring committee.

The trial was testing Bristol-Myers’ drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma.

The combination failed to show a statistically significant benefit in patients whose tumors had 1% or lower levels of the PD-L1 protein being targeted, the company said.

The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year.

Bristol-Myers shares were trading at $55.99 before the bell. (Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below